RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
RxSight (NASDAQ: RXST), an ophthalmic medical device company, reported disappointing preliminary Q2 2025 results and significantly lowered its full-year guidance. Revenue is expected to be $33.6 million, down 4% year-over-year and 11% sequentially.
The company sold 27,380 Light Adjustable Lenses (up 13% YoY but down 1% QoQ) and 40 Light Delivery Devices (down 49% YoY and 45% QoQ). The installed base grew 34% YoY to 1,084 LDDs.
RxSight revised its 2025 guidance downward, now expecting revenue of $120-130 million (previously $160-175 million), while increasing gross margin guidance to 72-74% and reducing operating expense projections to $145-155 million.
RxSight (NASDAQ: RXST), un'azienda di dispositivi medici oftalmici, ha riportato risultati preliminari del secondo trimestre 2025 deludenti e ha significativamente ridotto le previsioni per l'intero anno. Il fatturato previsto 猫 di 33,6 milioni di dollari, in calo del 4% su base annua e dell'11% rispetto al trimestre precedente.
L'azienda ha venduto 27.380 Lenti Regolabili con Luce (in aumento del 13% su base annua ma in calo dell'1% rispetto al trimestre precedente) e 40 Dispositivi di Erogazione della Luce (in diminuzione del 49% su base annua e del 45% rispetto al trimestre precedente). La base installata 猫 cresciuta del 34% su base annua, raggiungendo 1.084 LDD.
RxSight ha rivisto al ribasso le previsioni per il 2025, aspettandosi ora un fatturato di 120-130 milioni di dollari (precedentemente 160-175 milioni), aumentando per貌 la previsione del margine lordo al 72-74% e riducendo le spese operative previste a 145-155 milioni di dollari.
RxSight (NASDAQ: RXST), una empresa de dispositivos m茅dicos oft谩lmicos, report贸 resultados preliminares decepcionantes del segundo trimestre de 2025 y redujo significativamente sus previsiones para todo el a帽o. Se espera que los ingresos sean de 33,6 millones de d贸lares, una ca铆da del 4% interanual y del 11% secuencial.
La compa帽铆a vendi贸 27,380 Lentes Ajustables con Luz (un aumento del 13% interanual pero una ca铆da del 1% secuencial) y 40 Dispositivos de Entrega de Luz (una disminuci贸n del 49% interanual y del 45% secuencial). La base instalada creci贸 un 34% interanual hasta 1,084 LDD.
RxSight revis贸 a la baja sus previsiones para 2025, esperando ahora ingresos de 120-130 millones de d贸lares (anteriormente 160-175 millones), mientras que aument贸 la previsi贸n del margen bruto al 72-74% y redujo las proyecciones de gastos operativos a 145-155 millones de d贸lares.
RxSight (NASDAQ: RXST)電� 鞎堦臣 鞚橂旮瓣赴 須岇偓搿�, 2025雲� 2攵勱赴 鞓堧箘 鞁れ爜鞚� 旮半寑鞐� 氙胳箻歆� 氇豁枅雼り碃 氚滍憸頃橂┌ 鞐瓣皠 臧�鞚措崢鞀るゼ 韥矊 頃橅枼 臁办爼頄堨姷雼堧嫟. 毵れ稖鞚� 3,360毵� 雼煬搿� 鞝勲厔 雽�牍� 4%, 鞝勲秳旮� 雽�牍� 11% 臧愳唽頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
须岇偓电� 27,380臧滌潣 甏� 臁办爤 霠岇毳� 韺愲Г頄堨溂氅�(鞝勲厔 雽�牍� 13% 歃濌皜, 鞝勲秳旮� 雽�牍� 1% 臧愳唽), 40雽�鞚� 甏� 鞝勲嫭 鞛レ箻毳� 韺愲Г頄堧姅雿�(鞝勲厔 雽�牍� 49% 臧愳唽, 鞝勲秳旮� 雽�牍� 45% 臧愳唽) 靹れ箻 旮半皹鞚� 鞝勲厔 雽�牍� 34% 歃濌皜頃� 1,084 LDD鞐� 雼枅鞀惦媹雼�.
RxSight電� 2025雲� 毵れ稖 鞝勲鞚� 頃橅枼 臁办爼頃橃棳 1鞏� 2,000毵寏1鞏� 3,000毵� 雼煬搿� 鞓堨儊頃橂┌(旮办〈 1鞏� 6,000毵寏1鞏� 7,500毵� 雼煬), 齑濎澊鞚惦 臧�鞚措崢鞀る姅 72~74%搿� 靸來枼 臁办爼頃橁碃, 鞓侅梾牍勳毄 鞝勲鞚� 1鞏� 4,500毵寏1鞏� 5,500毵� 雼煬搿� 雮穭鞀惦媹雼�.
RxSight (NASDAQ : RXST), une soci茅t茅 de dispositifs m茅dicaux ophtalmiques, a publi茅 des r茅sultats pr茅liminaires d茅cevants pour le deuxi猫me trimestre 2025 et a consid茅rablement abaiss茅 ses pr茅visions pour l'ann茅e compl猫te. Le chiffre d'affaires attendu est de 33,6 millions de dollars, en baisse de 4 % en glissement annuel et de 11 % par rapport au trimestre pr茅c茅dent.
La soci茅t茅 a vendu 27 380 lentilles ajustables par lumi猫re (en hausse de 13 % en glissement annuel mais en baisse de 1 % par rapport au trimestre pr茅c茅dent) et 40 dispositifs de d茅livrance de lumi猫re (en baisse de 49 % en glissement annuel et de 45 % par rapport au trimestre pr茅c茅dent). La base install茅e a augment茅 de 34 % en glissement annuel pour atteindre 1 084 LDD.
RxSight a r茅vis茅 脿 la baisse ses pr茅visions pour 2025, s'attendant d茅sormais 脿 un chiffre d'affaires de 120-130 millions de dollars (contre 160-175 millions auparavant), tout en augmentant ses pr茅visions de marge brute 脿 72-74 % et en r茅duisant ses projections de d茅penses op茅rationnelles 脿 145-155 millions de dollars.
RxSight (NASDAQ: RXST), ein Unternehmen f眉r ophthalmologische Medizinprodukte, meldete entt盲uschende vorl盲ufige Ergebnisse f眉r das zweite Quartal 2025 und senkte seine Jahresprognose deutlich. Der Umsatz wird voraussichtlich 33,6 Millionen US-Dollar betragen, was einem R眉ckgang von 4 % im Jahresvergleich und 11 % im Quartalsvergleich entspricht.
Das Unternehmen verkaufte 27.380 Lichtanpassbare Linsen (plus 13 % im Jahresvergleich, aber minus 1 % im Quartalsvergleich) und 40 Lichtabgabeger盲te (minus 49 % im Jahresvergleich und minus 45 % im Quartalsvergleich). Die installierte Basis wuchs im Jahresvergleich um 34 % auf 1.084 LDDs.
RxSight hat seine Prognose f眉r 2025 nach unten korrigiert und erwartet nun einen Umsatz von 120-130 Millionen US-Dollar (zuvor 160-175 Millionen), w盲hrend die Bruttomargenprognose auf 72-74 % angehoben und die Betriebskostenprognose auf 145-155 Millionen US-Dollar gesenkt wurde.
- Installed base of Light Delivery Devices grew 34% YoY to 1,084 units
- Light Adjustable Lens sales volume increased 13% YoY
- Gross margin guidance increased to 72-74% from previous 71-73%
- Strong cash position with $227.5 million in cash and equivalents
- Q2 2025 revenue declined 4% YoY and 11% QoQ to $33.6 million
- Light Delivery Device sales dropped 49% YoY and 45% QoQ to just 40 units
- 2025 revenue guidance significantly reduced from $160-175M to $120-130M
- Operating expenses expected to increase 7-14% YoY despite revenue decline
Insights
RxSight significantly cuts 2025 revenue forecast amid alarming 45% quarterly drop in device placements, signaling serious adoption challenges despite healthy cash reserves.
RxSight's preliminary Q2 results reveal concerning operational challenges that have prompted a dramatic 24-31% reduction in full-year revenue guidance. The company posted quarterly revenue of
The most troubling metric is the precipitous
While procedure volumes using the Light Adjustable Lens showed modest
Management's acknowledgment of "second quarter underperformance" and pivot toward "supporting customer success" suggests the company is facing adoption barriers that require more intensive practice support rather than simply expanding the installed base.
The revised financial outlook is telling: full-year revenue now projected at
The company maintains a strong financial foundation with
ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) 鈥� RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time.
Preliminary Second Quarter 2025 Results
- Preliminary second quarter 2025 revenue is expected to be approximately
$33.6 million , representing a decrease of4% compared to the prior year period, and a decrease of11% compared to the first quarter of 2025, driven by:- The sale of 27,380 Light Adjustable Lenses (LAL庐/LAL+庐), representing a
1% decrease in procedure volume compared to the first quarter of 2025 and a13% increase in procedure volume compared to the second quarter of 2024; and - The sale of 40 Light Delivery Devices (LDD鈩), representing a
45% decrease compared to the first quarter of 2025 and a49% decrease compared to the second quarter of 2024. - As of June 30, 2025, the company鈥檚 installed base stood at 1,084 LDDs, which represents a
34% expansion compared to the installed base of 810 LDDs at the end of the second quarter of 2024.
- The sale of 27,380 Light Adjustable Lenses (LAL庐/LAL+庐), representing a
鈥淕uided by insights from our second quarter underperformance and building on our long-term vision, we are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices,鈥� said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. 鈥淏y deepening our engagement with our clinical partners, we believe we will be better positioned to ensure they can fully realize the benefits of adjustability and achieve the superior outcomes for their patients that ultimately drive further LAL adoption.鈥�
Revised 2025 Guidance
The company decreased its 2025 full-year revenue, increased its gross margin percentage and reduced its operating expense guidance as follows:
- Revenue in the range of
$120.0 million to$130.0 million , revised downward from the previous guidance range of$160.0 million to$175.0 million , representing an implied decrease of14% to7% compared to 2024; - Gross margin in the range of
72% to74% , an increase from the previous guidance range of71% to73% , and representing an implied increase of 130 basis points to 330 basis points compared to 2024; - Operating expense in the range of
$145.0 t o$155.0 million , representing an implied increase of7% to14% compared to 2024; - Operating expenses include non-cash stock-based compensation expense in the range of
$27.0 million to$30.0 million .
June 30, 2025 preliminary cash, cash equivalents and short-term investments are
The foregoing financial and operational results are preliminary estimates and complete, unaudited financial results for the second quarter of 2025 are expected to be announced on Thursday, August 7, 2025.
Conference Calls
On Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time, the company will host a conference call to discuss its preliminary second quarter 2025 revenue results and revised full year guidance. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8278360.
Separately, the company plans to report unaudited financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. Management will discuss these more comprehensive results during a conference call shortly following the announcement.
Both conference calls will also be broadcast live in listen-only mode via a link on the company鈥檚 investor relations website at . An archived recording of the calls will be available through the same link shortly after their completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight庐 Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens庐 (LAL庐/LAL+庐, collectively the 鈥淟AL鈥�), RxSight Light Delivery Device (LDD鈩�) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: statements concerning: the Company鈥檚 long-term vision and evolving commercial approach guided by insights from second quarter underperformance; plans to re-direct more focus toward supporting customer success within new and existing practices; expectations regarding deeper engagement with clinical partners; the Company鈥檚 belief that it will be better positioned to ensure clinical partners can fully realize the benefits of adjustability; and the potential to achieve superior patient outcomes that ultimately drive further LAL adoption; statements concerning the Company鈥檚 preliminary second quarter 2025 financial and operational results and the anticipated timing of announcing unaudited second quarter 2025 financial results; LDD and LAL sales growth trends; and the Company鈥檚 projected revenue, gross margin, operating expense and non-cash stock based compensation in 2025. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks described in the Company鈥檚 prior press releases and the Company鈥檚 filings with the Securities and Exchange Commission (SEC), including in Part I, Item 1A (Risk Factors) of the Company鈥檚 Annual Report on Form 10-K for the year-ended December 31, 2024, filed with the SEC on February 25, 2025, and any subsequent filings with the SEC.聽In some cases, you can identify forward-looking statements by terminology such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥渋ntends,鈥� 鈥渁nticipates,鈥� 鈥渂elieves,鈥� 鈥渆stimates,鈥� 鈥減redicts,鈥� 鈥減rojects,鈥� 鈥減otential,鈥� or 鈥渃ontinue鈥� or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
The foregoing financial and operational results are preliminary estimates. RxSight is in the process of finalizing its financial statements for the second quarter of 2025, and its actual results remain subject to completion of those financial statements and their review by its independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. RxSight鈥檚 actual, reported results of operations could differ based on completion of our quarter end closing procedures, final adjustments and developments that may arise prior to completion of its quarterly financial statements, and adjustments arising from the review by its independent registered public accounting firm. You should carefully review RxSight鈥檚 unaudited, consolidated financial statements for the second quarter of 2025 when they become available.
Company contact:
Shelley B. Thunen
Chief Financial Officer
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
FAQ
What caused RxSight (RXST) to lower its 2025 revenue guidance?
How many Light Adjustable Lenses did RxSight sell in Q2 2025?
What is RxSight's current installed base of Light Delivery Devices?
What is RxSight's cash position as of Q2 2025?
What are RxSight's revised gross margin expectations for 2025?
